Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$9.17 USD
+0.38 (4.32%)
Updated Aug 23, 2024 04:00 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Fulcrum Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 236 | 203 | 218 | 113 | 97 |
Receivables | 1 | 0 | 4 | 3 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 4 | 4 | 3 |
Total Current Assets | 242 | 208 | 226 | 120 | 100 |
Net Property & Equipment | 5 | 7 | 7 | 8 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 2 | 2 | 1 |
Total Assets | 258 | 227 | 235 | 130 | 110 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 5 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 10 | 9 | 7 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 5 | 15 | 4 |
Total Current Liabilities | 14 | 17 | 19 | 27 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 2 | 3 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 3 | 5 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 28 | 23 | 34 | 23 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 745 | 612 | 514 | 317 | 238 |
Retained Earnings | -510 | -412 | -302 | -222 | -151 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 235 | 199 | 212 | 95 | 87 |
Total Liabilities & Shareholder's Equity | 258 | 227 | 235 | 130 | 110 |
Total Common Equity | 235 | 199 | 212 | 95 | 87 |
Shares Outstanding | 61.80 | 52.00 | 40.50 | 32.60 | 23.30 |
Book Value Per Share | 3.81 | 3.83 | 5.22 | 2.92 | 3.74 |
Fiscal Year End for Fulcrum Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 274 | 213 | 236 | 257 | 278 |
Receivables | 2 | 0 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 5 | 5 | 4 |
Total Current Assets | 280 | 218 | 242 | 262 | 283 |
Net Property & Equipment | 4 | 5 | 5 | 6 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 294 | 233 | 258 | 279 | 300 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 5 | 9 | 8 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Total Current Liabilities | 13 | 11 | 14 | 14 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 19 | 23 | 23 | 25 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 755 | 751 | 745 | 741 | 737 |
Retained Earnings | -481 | -537 | -510 | -485 | -461 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 274 | 214 | 235 | 255 | 275 |
Total Liabilities & Shareholder's Equity | 294 | 233 | 258 | 279 | 300 |
Total Common Equity | 274 | 214 | 235 | 255 | 275 |
Shares Outstanding | 62.40 | 62.10 | 61.80 | 61.80 | 61.80 |
Book Value Per Share | 4.39 | 3.44 | 3.81 | 4.13 | 4.46 |